GlassScriptPhysician profile
Michelle J Kwon
NPI 1447630744
$12,320.88
in general payments reported to CMS, 2019-2025
20 companies · $1,936 in 2025
The $1,936 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,076 · 2020: $755 · 2021: $1,241 · 2022: $1,346 · 2023: $2,078 · 2024: $1,889 · 2025: $1,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,903.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,557.52 | 2022-2025 | Infuse, Infuse Svs, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $3,092.54 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $1,957.56 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,222.95 | 2019-2025 | Precision7, Total30, Dailies Total1 |
| Coopervision INC. | $682.56 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Horizon Therapeutics Plc | $489.87 | 2021-2023 | Tepezza |
| Allergan, INC. | $216.52 | 2021-2022 | |
| Dompe US, INC. | $149.85 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $135.76 | 2024 | Xdemvy |
| Shire North American Group INC | $125.00 | 2019 | |
| Amgen INC. | $125.00 | 2025 | Tepezza |
| Rxsight INC | $118.47 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Glaukos Corporation | $106.11 | 2022 | |
| Astellas Pharma US INC | $87.98 | 2024 | Izervay |
| Lkc Technologies, INC. | $79.86 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $60.36 | 2019 | |
| Abbvie INC. | $48.97 | 2022-2023 | |
| Oyster Point Pharma, INC. | $26.18 | 2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $19.98 | 2020 | |
| Thea Pharma INC. | $17.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.